Moleculin Biotech Files 8-K with Financials and Disclosures

Ticker: MBRX · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1659617

Sentiment: neutral

Topics: financial-reporting, regulation-fd, exhibits

Related Tickers: MBRX

TL;DR

Moleculin Biotech (MBRX) filed an 8-K on Aug 6th covering financials & Reg FD. HQ in Houston.

AI Summary

Moleculin Biotech, Inc. filed an 8-K on August 6, 2025, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 5300 Memorial Drive, Suite 950, Houston, TX 77007, and its telephone number is (713) 300-5160. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing provides essential updates on Moleculin Biotech's financial reporting and regulatory disclosures, which are crucial for investors to assess the company's current status and compliance.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial statements and exhibits, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What specific financial statements are being filed with this 8-K?

The filing indicates 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the provided text.

What is the primary purpose of this 8-K filing for Moleculin Biotech?

The primary purpose is to report on Regulation FD Disclosure and to file Financial Statements and Exhibits as of August 6, 2025.

Where are Moleculin Biotech's principal executive offices located?

Moleculin Biotech's principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.

When is Moleculin Biotech's fiscal year-end?

Moleculin Biotech's fiscal year ends on December 31.

What is the company's SEC file number?

The SEC file number for Moleculin Biotech, Inc. is 001-37758.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding Moleculin Biotech, Inc. (MBRX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing